In the present study, we aimed to assess the quantitative and qualitative results of STANDARD E TB-Feron ELISA and STANDARD F TB-Feron FIA (IFN-γ) by comparing them with the QuantiFERON-TB Gold Plus (QuantiFERON) in a population from the Republic of Moldova, an Eastern European country with a TB incidence three times higher than the European regional average (76 cases per 100,000, WHO estimate for 2023) [1]. Here, IFNG is linked to tuberculosis.